In addition to those beneficial effects, recent studies demonstrated that liraglutide inhibits the calcification of various cell types (e.g., vascular smooth muscle cell and embryonic osteoblast cell) through binding to GLP-1R and subsequently activating PI3K/Akt signaling [22,23,24], suggesting that liraglutide may also have effects on VIC calcification and could serve as a potential anti-CAVD therapeutic drug. Here, GLP1R is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.